Eric L. Bolda

Array ( [id] => 19142498 [patent_doc_number] => 20240141339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => Oligonucleotide Comprising Inosine for Treating DMD [patent_app_type] => utility [patent_app_number] => 18/178841 [patent_app_country] => US [patent_app_date] => 2023-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18178841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537812 [patent_doc_number] => 20230242913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => STING-DEPENDENT ACTIVATORS FOR TREATMENT OF DISEASE [patent_app_type] => utility [patent_app_number] => 18/176396 [patent_app_country] => US [patent_app_date] => 2023-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16371 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18536005 [patent_doc_number] => 20230241092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => LIPID NANOPARTICLES FOR DELIVERY OF STING-DEPENDENT ADJUVANTS [patent_app_type] => utility [patent_app_number] => 18/176406 [patent_app_country] => US [patent_app_date] => 2023-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39842 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18523058 [patent_doc_number] => 20230233712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXBETA REDUCTASE [patent_app_type] => utility [patent_app_number] => 18/174793 [patent_app_country] => US [patent_app_date] => 2023-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10165 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18174793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844898 [patent_doc_number] => 20230407302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => NOVEL EFFICACIOUS MICRORNA-30C ANALOGS REDUCE APOLIPOPROTEIN B SECRETION IN HUMAN LIVER CELLS [patent_app_type] => utility [patent_app_number] => 18/164699 [patent_app_country] => US [patent_app_date] => 2023-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649804 [patent_doc_number] => 20230295628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => NUCLEIC ACID COMPLEX [patent_app_type] => utility [patent_app_number] => 18/163506 [patent_app_country] => US [patent_app_date] => 2023-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17448 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18163506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034481 [patent_doc_number] => 20240084296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => SINGLE-STRANDED OLIGONUCLEOTIDE [patent_app_type] => utility [patent_app_number] => 18/162942 [patent_app_country] => US [patent_app_date] => 2023-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 528 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739939 [patent_doc_number] => 20230348908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => RNA Interactome of Polycomb Repressive Complex 1 (PRC1) [patent_app_type] => utility [patent_app_number] => 18/156360 [patent_app_country] => US [patent_app_date] => 2023-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19474080 [patent_doc_number] => 12104157 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Targeted inhibition using engineered oligonucleotides [patent_app_type] => utility [patent_app_number] => 18/155163 [patent_app_country] => US [patent_app_date] => 2023-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 62 [patent_no_of_words] => 38285 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 265 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18155163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511652 [patent_doc_number] => 20230227829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING EPILEPSY [patent_app_type] => utility [patent_app_number] => 18/154241 [patent_app_country] => US [patent_app_date] => 2023-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 152161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -131 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436408 [patent_doc_number] => 20230183702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => SINGLE-STRANDED OLIGONUCLEOTIDE [patent_app_type] => utility [patent_app_number] => 18/152504 [patent_app_country] => US [patent_app_date] => 2023-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 552 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18152504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497716 [patent_doc_number] => 20230220396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/150827 [patent_app_country] => US [patent_app_date] => 2023-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68196 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18150827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19279943 [patent_doc_number] => 20240216416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => METHOD OF TREATING BREAST CANCER IN A SUBJECT BY INHIBITING TUBB2B [patent_app_type] => utility [patent_app_number] => 18/148466 [patent_app_country] => US [patent_app_date] => 2022-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18148466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817808 [patent_doc_number] => 20230392148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => REDUCING BETA-CATENIN EXPRESSION TO POTENTIATE IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/147549 [patent_app_country] => US [patent_app_date] => 2022-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18147549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844897 [patent_doc_number] => 20230407301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => ANTISENSE OLIGOMER COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/145604 [patent_app_country] => US [patent_app_date] => 2022-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26679 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18145604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18583146 [patent_doc_number] => 20230265405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ENGINEERED NUCLEASES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/069387 [patent_app_country] => US [patent_app_date] => 2022-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879481 [patent_doc_number] => 20240002850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => SIRT1-saRNA Compositions and Methods of Use [patent_app_type] => utility [patent_app_number] => 18/086209 [patent_app_country] => US [patent_app_date] => 2022-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18086209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18685152 [patent_doc_number] => 11780869 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Deuterium-stabilised ribonucleic acid (RNA) molecules displaying increased resistance to thermal and enzymatic hydrolysis, aqueous compositions comprising stabilised RNA molecules and methods for making same [patent_app_type] => utility [patent_app_number] => 18/080919 [patent_app_country] => US [patent_app_date] => 2022-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 34 [patent_no_of_words] => 11864 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18080919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20357562 [patent_doc_number] => 12473549 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Splicing-dependent transcriptional gene silencing or activation [patent_app_type] => utility [patent_app_number] => 18/065086 [patent_app_country] => US [patent_app_date] => 2022-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 98 [patent_no_of_words] => 22738 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18469204 [patent_doc_number] => 20230203488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => MODIFIED RIBONUCLEIC ACIDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/075085 [patent_app_country] => US [patent_app_date] => 2022-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37159 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18075085 [rel_patent_id] =>[rel_patent_doc_number] =>)